Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech, Gary Albert, Iksung Cho, Andreana Robertson, Patricia Reed, Susan Neal, Joyce S Plested, Mingzhu Zhu, Shane Cloney-Clark, Haixia Zhou, Gale Smith, Nita Patel, Matthew B Frieman, Robert E Haupt, James Logue, Marisa McGrath, Stuart Weston, Pedro A Piedra, Chinar Desai, Kathleen Callahan, Maggie Lewis, Patricia Price-Abbott, Neil Formica, Vivek Shinde, Louis Fries, Jason D Lickliter, Paul Griffin, Bethanie Wilkinson, Gregory M Glenn, Cheryl Keech, Gary Albert, Iksung Cho, Andreana Robertson, Patricia Reed, Susan Neal, Joyce S Plested, Mingzhu Zhu, Shane Cloney-Clark, Haixia Zhou, Gale Smith, Nita Patel, Matthew B Frieman, Robert E Haupt, James Logue, Marisa McGrath, Stuart Weston, Pedro A Piedra, Chinar Desai, Kathleen Callahan, Maggie Lewis, Patricia Price-Abbott, Neil Formica, Vivek Shinde, Louis Fries, Jason D Lickliter, Paul Griffin, Bethanie Wilkinson, Gregory M Glenn
Abstract
Background: NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.
Methods: We initiated a randomized, placebo-controlled, phase 1-2 trial to evaluate the safety and immunogenicity of the rSARS-CoV-2 vaccine (in 5-μg and 25-μg doses, with or without Matrix-M1 adjuvant, and with observers unaware of trial-group assignments) in 131 healthy adults. In phase 1, vaccination comprised two intramuscular injections, 21 days apart. The primary outcomes were reactogenicity; laboratory values (serum chemistry and hematology), according to Food and Drug Administration toxicity scoring, to assess safety; and IgG anti-spike protein response (in enzyme-linked immunosorbent assay [ELISA] units). Secondary outcomes included unsolicited adverse events, wild-type virus neutralization (microneutralization assay), and T-cell responses (cytokine staining). IgG and microneutralization assay results were compared with 32 (IgG) and 29 (neutralization) convalescent serum samples from patients with Covid-19, most of whom were symptomatic. We performed a primary analysis at day 35.
Results: After randomization, 83 participants were assigned to receive the vaccine with adjuvant and 25 without adjuvant, and 23 participants were assigned to receive placebo. No serious adverse events were noted. Reactogenicity was absent or mild in the majority of participants, more common with adjuvant, and of short duration (mean, ≤2 days). One participant had mild fever that lasted 1 day. Unsolicited adverse events were mild in most participants; there were no severe adverse events. The addition of adjuvant resulted in enhanced immune responses, was antigen dose-sparing, and induced a T helper 1 (Th1) response. The two-dose 5-μg adjuvanted regimen induced geometric mean anti-spike IgG (63,160 ELISA units) and neutralization (3906) responses that exceeded geometric mean responses in convalescent serum from mostly symptomatic Covid-19 patients (8344 and 983, respectively).
Conclusions: At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell responses that were biased toward a Th1 phenotype. (Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04368988).
Copyright © 2020 Massachusetts Medical Society.
Figures
References
- Wang Y, Zhang Y, Yu Q, Zhu K. Convalescent plasma coupled with medications for the treatment of a severe COVID-19 patient: drugs analysis and pharmaceutical care based on the newly established guidelines for COVID-19 remedy. Front Pharmacol 2020;11:966-966.
- World Health Organization. Pneumonia of unknown cause — China. 2020. ().
- World Health Organization. Coronavirus disease (COVID-19): situation report 194: data as received by WHO from national authorities by 10:00 CEST, 1 August 2020. 2020. ().
- World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. 2020. ().
- Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157-160.
- Bengtsson KL, Song H, Stertman L, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine 2016;34:1927-1935.
- Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV — a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7:226-236.
- Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 2020;17:613-620.
- Tian J-H, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice. June 30, 2020. (). preprint.
- Mandolesi M, Sheward DJ, Hanke L, et al. SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses. July 31, 2020. (). preprint.
- Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260-1263.
- Reimer JM, Karlsson KH, Lövgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L. Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One 2012;7(7):e41451-e41451.
- Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials: guidance for industry. Rockville, MD: Food and Drug Administration, September 2007.
- Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. Bethesda, MD: National Institute of Allergy and Infectious Diseases, July 2017.
- Law B, Sturkenboom M. D2.3 priority list of adverse events of special interest: COVID-19. SPEAC. 2020. ().
- Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020. August 12 (Epub ahead of print).
- Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 2020. July 30 (Epub ahead of print).
- Buchwald AG, Graham BS, Traore A, et al. RSV neutralizing antibodies at birth predict protection from RSV illness in infants in the first three months of life. Clin Infect Dis 2020. May 28 (Epub ahead of print).
- Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003;22:823-827.
- Carbonell-Estrany X, Simões EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010;125(1):e35-e51.
- Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020;383:415-425.
- Liu L, To KK-W, Chan K-H, et al. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg Microbes Infect 2020;9:1664-1670.
- Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 2020;584:353-363.
- Center for Biologics Evaluation and Research. Development and licensure of vaccines to prevent COVID-19: guidance for industry. Rockville, MD: Food and Drug Administration, June 2020.
- Fries L, Shinde V, Stoddard JJ, et al. Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults. Immun Ageing 2017;14:8-8.
- Muňoz FM, Swamy GK, Hickman SP, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis 2019;220:1802-1815.
- Glenn GM, Fries LF, Thomas DN, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 2016;213:411-422.
- Shinde V, Cai R, Plested J, et al. Induction of cross-reactive hemagglutination inhibiting antibody and polyfunctional CD4+ T-cell responses by a recombinant Matrix-M-adjuvanted hemagglutinin nanoparticle influenza vaccine. May 18, 2020. (). preprint.
- Shinde V, Fries L, Wu Y, et al. Improved titers against influenza drift variants with a nanoparticle vaccine. N Engl J Med 2018;378:2346-2348.
- Shinde V, Cho I, Plested JS, et al. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a randomized controlled trial. May 18, 2020. (). preprint.
Source: PubMed